Visual outcomes and number of injections in anti-VEGF treatment studies
| Study | Baseline | Year 1 | Year 2 | Year 3 | ||||||||
| n | Age (years) | VA* | n | Change of VA*† | IVI | n | Change of VA*† | IVI | n | Change of VA*† | IVI | |
| MARINA‡ | 77 | 54 | +7 | monthly | +7 | monthly | NA | NA | ||||
| ANCHOR‡ | 76 | 47 | +11 | 11.2 | +11 | 10.1 | NA | NA | ||||
| VIEW studies§ | 76 | 54 | +8 | 7.5 | +8 | 3.6 | NA | NA | ||||
| CATT¶ | 79 | 60 | +6 | 7.7 | +5 | 6.4 | NA | NA | ||||
| AURA | 77 | 55 | +2 | 5 | +1 | 2.2 | NA | NA | ||||
| Tufail et al 2014 | 79 | 55 | +2 | 5 | +1 | 4 | −2 | 4 | ||||
| Current study¶** | ||||||||||||
| All eyes | 1345 | 80 | 60 | 733 | +2 | 5.7 | 349 | +2 | 4.7 | 193 | ±0 | 4.9 |
| Baseline VA 0.065–0.5 | 947 | 80 | 58 | 539 | +4 | 5.8 | 245 | +5 | 4.8 | 131 | +4 | 5.0 |
| Baseline VA 0.065–0.8 | 1146 | 80 | 62 | 663 | +2 | 5.7 | 314 | +2 | 4.7 | 173 | ±0 | 5.0 |
*All VA scores in Early Treatment Diabetic Retinopathy Study letters IVI.
†Change of VA from baseline.
‡Ranibizumab 0.5 mg monthly treatment arm (Brown et al 2006; Rosenfeld et al 2006).
§Aflibercept treatment arm (Heier et al 2012).
¶Bevacizumab pro re nata treatment arm (Martin et al 2011).
**Last-Observation-Carried-Forward analysis.
IVI, intravitreal injections; NA, not available; VA, visual acuity.